Loading...
•
Jun 30, 2020
Pacira Q2 2020 Earnings Report
Pacira BioSciences reported a decrease in revenue due to the impact of COVID-19, but saw a recovery in EXPAREL sales in June and strengthened its financial position through recent financing.
Key Takeaways
Pacira BioSciences reported a decrease in total revenues to $75.5 million and a GAAP net loss of $7.3 million for Q2 2020, impacted by the COVID-19 pandemic. However, EXPAREL sales showed recovery in June, and the company completed a financing that improved its financial foundation.
Total revenues decreased by 26% to $75.5 million compared to Q2 2019.
EXPAREL net product sales decreased by 26% to $73.0 million compared to Q2 2019.
GAAP net loss was $7.3 million, or $0.17 per share, compared to a net income of $2.7 million in Q2 2019.
The company issued $402.5 million in convertible senior notes and concluded its EXPAREL agreement with DePuy Synthes.
Revenue by Segment
Forward Guidance
Due to the rapidly changing variables related to the COVID-19 pandemic, the company does not have sufficient visibility to accurately forecast the impact of the pandemic and is currently not providing full-year 2020 financial guidance.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...